Axsome Therapeutics, Inc., New York, NY, has become the latest sponsor entranced by the analgesic potential of meloxicam to stumble on the BCS class II drug’s virtual insolubility.
Like others before it, Axsome has proposed to unlock the non-steroidal anti-inflammatory drug’s potential with a trademarked technology, only to run into difficulty during US Food